36th week of 2008 patent applcation highlights part 38 |
Patent application number | Title | Published |
20080213316 | Destruction of spores through glycoconjugate enhanced phagocytosis - Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method includes the steps of modifying a surface of a bacterial spore to increase adherence to a phagocyte; and ingesting the adherence-increased spore with the phagocyte, thereby destructing and killing the spore by blocking spore-induced phagocyte cell death, while increasing phagocyte activation level and production of antimicrobial and cytocidal agents such as NO and inflammatory cytokines. The adherence of spore to a phagocyte is increased after the surface thereof is coated with a glycoconjugate to form a glycoconjugate-coated spores. The glycoconjugate-coated spores also increase ingestion of the spores by phagocytes and facilitate phagosome-lysosome fusion, which in turn results in destruction and killing of bacterial spores via phagocytosis. The method enhances adherence, ingestion, destruction and killing of bacterial spores via phagocytes, which otherwise may be resistant to phagocytosis. | 2008-09-04 |
20080213317 | AVIAN E. COLI VACCINE FOR PROTECTION AGAINST COLIBACILLOSIS - A genetic deletion mutant live | 2008-09-04 |
20080213318 | Malaria MSP-1 C-terminal enhanced subunit vaccine - A vaccine or immunogenic composition is described that contains recombinantly produced, secreted, forms of malaria MSP-1 C-terminal subunit proteins from any of the | 2008-09-04 |
20080213319 | CHEMOREPULSION OF CELLS - The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes. | 2008-09-04 |
20080213320 | Compositions for treatment of gastro-esophageal reflux disorders - The present invention provides compositions for treatment of gastro-esophageal reflux disorders. The compositions include at least two of the following: (i) one or more digestive enzymes; (ii) one or more probiotics; and (iii) stevia. Also provided are processes for preparing the compositions useful for treatment of gastro-esophageal reflux disorders, and methods of treating subjects against gastro-esophageal reflux disorders, which include administering to a subject a therapeutically effective amount of the compositions of the present invention. | 2008-09-04 |
20080213321 | DERMABRASION DEVICES AND SYSTEMS - In general, the invention relates to the design and fabrication of devices and systems suitable for dermabrasion. | 2008-09-04 |
20080213322 | Method for the hydrophobic treatment of pigment particles and the personal care compositions comprising said pigment particles - The present invention provides a method for the hydrophobic treatment of pigment particles comprising contacting said pigment particles with one or more silicone-based materials, that are substantially free of silicon-hydrogen bonds and fluorine, producing hydrophobic, non-covalently bound, modified pigment particles. Additionally, the present invention provides personal care compositions comprising said modified or coated pigment particles. | 2008-09-04 |
20080213323 | Use of active principles which are capable of enhancing the content of ceramides, as protective agent for delicate lips - The present invention relates to the field of preventive and/or curative protection of delicate lips. | 2008-09-04 |
20080213324 | Amphiphilic or lipophilic polar functionalized fullerenes and their uses - Described herein are synthetically modified fullerene molecules, wherein the fullerene is preferably ellipsoid in shape with an equatorial band and two opposing poles, comprising an adduct at one or both poles, at least one adduct being a hydrophobic chemical moiety capable of anchoring the fullerene on or in a lipid membrane. | 2008-09-04 |
20080213325 | POWDER MIXTURE CONSISTING OF TITANIUM DIOXIDE, ZINC OXIDE AND ZINC/TITANIUM MIXED OXIDE - A powder mixture consisting of zinc/titanium mixed oxide particles, titanium dioxide particles and zinc oxide particles, wherein the zinc/titanium mixed oxide particles have a composition according to the formula (ZnO) | 2008-09-04 |
20080213326 | Method For Producing Aqueous Active Substance Compositions Of Active Substances That Are Hardly Soluble In Water - The present invention relates to a process for preparing aqueous active compound compositions of active compounds which are poorly soluble in water, in particular of active compounds for the protection of crops and materials. Moreover, the invention relates to the active compound compositions obtainable by the process and to their use for controlling harmful organisms in plants and in the protection of materials. | 2008-09-04 |
20080213327 | Method of Deparasitizing and Parasiticidal Powder - Method using a parasiticidal powder typically comprising from 1 to 15% by weight of silica and from 85 to 99% of alkali metal bicarbonate. | 2008-09-04 |
20080213328 | NANOSILVER-CONTAINING PRESERVATION ARTICLES, AND THE PREPARATION PROCESS AND THE USES THEREOF - A preservation article is provided which includes nanosilver-containing anti-bacterial granules blended with plastic materials. The granules blended with the plastic materials are present in the plastic materials in an amount of 0.1 to 0.8 weight percentage based on the weight of the plastic materials. | 2008-09-04 |
20080213329 | Method of Delivering a Biologically Active Agent - A method of delivering a biologically active agent to a target site comprising exposing a surface of a non-target carrier organism to a carrier comprising at least one biologically active agent, wherein the non-target carrier organism delivers the biologically active agent to the target site. | 2008-09-04 |
20080213330 | Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons - A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent. | 2008-09-04 |
20080213331 | METHODS AND DEVICES FOR RENAL NERVE BLOCKING - A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery. | 2008-09-04 |
20080213332 | Cells Isolated from Placenta, Device for Isolating Same, and Uses Thereof - A method of processing an organ is disclosed. The method comprises: (a) placing an organ in a sealable container; (b) disrupting the structure of said organ to yield a cell suspension; and (c) transferring said cell suspension to a sealable cell-suspension storage container, thereby isolating cells of said organ, wherein said sealable container, wherein said disrupting and said transferring are all performed substantially in a continuous vessel. | 2008-09-04 |
20080213333 | Methods and compositions for fostering and preserving bone growth - A method for augmenting bone in a subject in need thereof including installing within an interior portion of a bone located in the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, wherein the scaffold serves as a support for the formation of new bone within the bone interior portion, and administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one anabolic agent in the subject. The method may further include administering at least one anti-resorptive agent to the subject in an amount sufficient to substantially prevent resorption of new bone growth. In another embodiment, the method may further include a step of mechanically inducing an increase in osteoblast activity in the subject, wherein the elevation in blood concentration of the anabolic agent and the increase in osteoblast activity at least partially overlap in time. | 2008-09-04 |
20080213334 | POLYELECTROLYTE MEDIA FOR BIOACTIVE AGENT DELIVERY - The invention provides polyelectrolyte hydrogels, blends, and multilayers for the controlled release of bioactive agents from implantable medical devices coated with or containing such media. | 2008-09-04 |
20080213335 | GRAFT PROSTHESIS, MATERIALS AND METHODS - A graft prostheses ( | 2008-09-04 |
20080213336 | POLYMETHYLMETHACRYLATE REVISION BONE CEMENT - The invention relates to a PMMA revision bone cement having powder and liquid component, in which the powder component contains two or more granular antibiotics whose grain size distribution is equal in that the main screening fraction each of the individual antibiotics is in the same grain size range, in particular in the range of 100-250 μm or 150-250 μm. | 2008-09-04 |
20080213337 | DRUG IMPLANT CARRIER FOR DRUG DELIVERY - The present invention relates to ceramic precursor material exhibiting injectability arid properties that make the material suitable as a carrier material used in drug delivery. According to the invention this is accomplished by selecting a microstructure based on pre-reacted phases and after injection established phases, which contain anti-infective and/or anti-inflammatory drugs. The present invention also relates to a cured ceramic material and a method of manufacturing said cured material. The precursor and the cured ceramic material according to the present invention can suitably be used for filling orthopaedic cavities and other bone voids. | 2008-09-04 |
20080213338 | IMPLANT STENT WITH A RETINOID FOR IMPROVED BIOCOMPATIBILITY - An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof. | 2008-09-04 |
20080213339 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin - The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a mixture of the active ingredients, in micronized form, preferably mixed with at least one flavonoid derivative or a polypeptide or with a mixture of such compounds. | 2008-09-04 |
20080213340 | Transformed Plant Cell Expressing Tandem Repeats of Beta-Amyloid Gene and Plant Produced by the Same - The present invention relates to a transformed plant cell expressing β-amyloid gene, which is known as a causal substance of senile dementia in human, a transformed plant and a preparation method of the same, more particularly, to a transformed plant cell expressing tandem repeats of β-amyloid gene, a transformed plant produced by tissue-culturing the above cells and a preparation method of the same. The transformed plant of the present invention expresses multiple β-amyloid protein, so that the plant can be effectively used for the preparation of an oral vaccine composition for the prevention of senile dementia in human. | 2008-09-04 |
20080213341 | Butyric Acid Esters of Carbohydrates and Carbohydrate Polyols - The invention relates to butyric acid esters or butyrate esters of carbohydrates and carbohydrate polyols and their use as a butyrate carrier and butyrate source for the gastrointestinal tract, in particular for the prevention and treatment of diseases of the gastrointestinal tract, especially of the large intestine. | 2008-09-04 |
20080213342 | Hop acids as a replacement for antibiotics in animal feed - A method of using hop acids for increasing food and energy uptake from feed by livestock is described which includes delivering the hop acids for oral ingestion to the animals by mixing the acids with livestock feed. The acids are mixed with the feed in an amount to inhibit certain types of undesirable bacteria in the livestock's digestive system, thereby increasing the production of propionate and lactate and decreasing the production of methane gas. | 2008-09-04 |
20080213343 | Oral, Quickly Disintegrating Film, which Cannot be Spit Out, for an Antiemetic or Antimigraine Agent - Film-form, single-layered, cavity-free preparation free of surfactants, effervescent additive and taste masker and comprising one or more film former(s), one or more gel former(s) and one or more active ingredient(s) from the group of anti-emetics and anti-migraine agents. | 2008-09-04 |
20080213344 | Wound dressing and method for controlling severe, life-threatening bleeding - This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer, a polyacrylic polymer or a combination thereof, The kind of severe, life-threatening bleeding contemplated by this invention is typically of the type not capable of being stanched when a conventional gauze wound dressing is applied with conventional 10 pressure to the subject wound. The wound dressing being capable of substantially stanching the flow of the severe life-threatening bleeding from the wound by adhering to the wound site, to seal the wound, to accelerate blood clot formation at the wound site, to reinforce clot formation at the wound site and prevent bleed out from the wound site, and to substantially prohibit the flow of 15 blood out of the wound site. | 2008-09-04 |
20080213345 | Delivering Iron to an Animal - The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal. | 2008-09-04 |
20080213346 | Preparation of Nanoliposome-Encapsulating Proteins and Protein-Encapsulated Nanoliposome - Preparing a nanoliposome for encapsulating a protein includes preparing a dispersion by dispersing a phospholipid in an aqueous solution containing the protein, applying a shearing force to the dispersion; adding an additional amount of the phospholipid to the result of the step of applying the shearing force to the dispersion and then applying a shearing force higher than that of the step of applying the shearing force to the dispersion, and repeating the step of adding the additional amount of the phospholipid and applying the higher shearing force with an additional amount of the phospholipid and a shearing force higher than the prior step to obtain a nanoliposome having a desired diameter and encapsulation efficiency. | 2008-09-04 |
20080213347 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof - Novel ligand antagonists of the RAR receptors have the following structural formula (I): | 2008-09-04 |
20080213348 | Agents for gene therapy of cerebrovascular disorders - The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and the suppression of infarcted areas in patients for whom appropriate treatment methods were unavailable until now. | 2008-09-04 |
20080213349 | Liposome Complexes Containing Pharmaceutical Agents and Methods - Liposome complexes are provided for site-specific delivery of pharmaceutical agents with improved targeting efficiency. The liposome complexes include a pharmaceutical agent associated with the liposome; a sialic acid-containing molecule associated with the liposome; and optionally a targeting agent attached to the sialic acid-containing molecule. The invention also provides methods of making liposome complexes and their in vivo administration. | 2008-09-04 |
20080213350 | Encapsulation of nucleic acids in liposomes - Complexes of nucleic acid and cationic polymer, which are encapsulated in liposomes for the purpose of delivering nucleic acid and methods for producing encapsulated complexes. | 2008-09-04 |
20080213351 | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease - The present invention relates to pharmaceutical compositions comprising liposomes and methods of using such liposomes to prevent, treat, or manage a variety of diseases and/or bodily conditions. The liposomes may comprise large unilamellar vesicles (LUVs) alone or in combination with multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or other therapeutics. The invention relates to liposomes having certain diameters administered to patients using specific doses and/or dosing regimens. | 2008-09-04 |
20080213352 | Liposome carriers for in vivo delivery of fullerenes - Described herein are pharmaceutically acceptable compositions comprising fullerene molecules dispersed in vesicles comprising phosphatidylcholine (PC) phospholipid molecules and non-PC phospholipid molecules suspended in aqueous solution. In preferred embodiments, the phospholipid molecules are substantially uniformly organized into vesicles composed of one or more lipid bilayers and the fullerene molecules are substantially uniformly distributed within the lipid bilayers of the vesicles. Methods of forming these fullerene containing liposomes are also described. Such fullerene containing liposomes provide carriers for delivery of fullerenes for cosmetic, therapeutic, and imaging applications among other uses. | 2008-09-04 |
20080213353 | Method for preparing liposome formulations with a predefined release profile - The present invention provides a novel tool for designing a release profile of an active agent from a liposome in to which it is loaded. According to the invention, a method is provided for preparing a liposomal formulation for delivery of an active agent to a target, the release of said active agent from the liposome being designed to have a release profile in which the release is sustained for a time period to achieve an optimal effect of the active agent at said target, the method comprising preparing a liposomal formulation, wherein the liposome is loaded with said active agent and with a selected counter ion, the counter ion and the active agent interacting together to aggregate and/or to form a precipitate within the liposome, the counter ion being selected such that the release of the active agent from the liposome has said release profile. | 2008-09-04 |
20080213354 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. | 2008-09-04 |
20080213355 | Method and System for in Vivo Drug Delivery - A system and method for polymeric drug delivery vehicles activated by ultrasound is disclosed herein. The system and method include polymeric particles, partially filled with a gas or a gas precursor, and partially filled with a liquid containing a drug. The drug is then released locally by application of ultrasound. Because the drug is dissolved, the delivery thereof is more efficient than for drugs incorporated with or in the polymeric shell of such particles. | 2008-09-04 |
20080213356 | Pharmaceutical Composition Containing Hmg-Coa Reductase Inhibitor And Method For The Preparation Thereof - The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, and a process for the preparation thereof by direct compression. | 2008-09-04 |
20080213357 | Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications - The present disclosure relates to novel nutritional and cosmeceutical compositions comprising an oil extracted from the seeds of Boraginaceae, particularly | 2008-09-04 |
20080213358 | Method And Device For Ultrasound-Pressing A Tablet Or A Multiparticulate Medicament - The present invention relates to a method and a device for shaping a pharmaceutically active substance in the form of powders, granules, multiparticulate medicaments, in particular pellets and microcapsules, for the production of a tablet or a multiparticulate medicament by means of ultrasound, with an ultrasound generator, a sonotrode and a mould, into which the pharmaceutically active substance can be poured. | 2008-09-04 |
20080213359 | Calcium sulfate based nanoparticles - The present invention provides a method for facilitating repair of an area of bone by providing hemihydrate calcium sulfate particles, mixing the particles with an aqueous solution to obtain a paste, applying the paste to an area of bone in need of repair, and allowing the paste to set. | 2008-09-04 |
20080213360 | DRY GRANULATION BINDERS, PRODUCTS, AND USE THEREOF - A method for the preparation of microcrystalline cellulose containing tablets by roller compaction followed by tabletting is disclosed. A tablet formulation is converted to a dry granulate by roller compaction, and the dry granulate lubricated dry granulate and compacted to a tablet. The tablet formulation comprises at least one active, an microcrystalline cellulose containing material, and, optionally other pharmaceutically acceptable excipients. The microcrystalline cellulose containing material has a maximum primary compaction tensile strength of at least 9 MPa or at least 9.5 MPa and a secondary compaction tensile strength of at least 5 MPa, at least 5.5 MPa, or at least 6 MPa. A method for evaluating binders is also disclosed. | 2008-09-04 |
20080213361 | Method for Production of Directly Compressible Ibuprofen Formulations - A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m | 2008-09-04 |
20080213362 | COMPOSITIONS AND METHODS USING TORSEMIDE - Dosage forms containing torsemide as the active ingredient, preferably provided at a relatively low dose or strength, are disclosed. The dosage forms can, be formulated as a tablet having a novel scoring pattern enabling division of the tablet to provide unique doses and dosing regimens to be administered to a patient in need of treatment or prevention using torsemide. | 2008-09-04 |
20080213363 | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa - Compositions, methods, and formulations for delivering 5-HT | 2008-09-04 |
20080213364 | Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation - The present invention provides pharmaceutical compositions for oral administration comprising pyridoxal-5′-phosphate wherein the compositions contain an amount of pyridoxal-5-phosphate of at least 50% w/w and methods of preparing the pharmaceutical compositions. The present invention also provides a pre-blend for the manufacture of a pyridoxal 5′-phosphate oral dosage form comprising pyridoxal 5′-phosphate and microcrystalline cellulose, wherein the pre-blend contains an amount pyridoxal-5-phosphate greater than or equal to 80% w/w. | 2008-09-04 |
20080213365 | UNUSUALLY STABLE GLASSES AND METHODS FOR FORMING SAME - The present invention provides vapor deposition-methods that overcome the kinetic restrictions imposed by more conventional vapor deposition processes and liquid-cooling techniques to form amorphous molecular solids with greatly enhanced-stabilities. The present methods produce amorphous molecular solids having stabilities, as measured by fictive temperature, that cannot be achieved using liquid-cooling methods. | 2008-09-04 |
20080213366 | Therapeutic Compositions - The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described. | 2008-09-04 |
20080213367 | WATER SOLUBLE CONCENTRIC MULTI-WALL CARBON NANO TUBES - The present invention relates to water soluble carbon nano tubes (WSNT) which have been made function by functionalizing with carboxylic acid groups. The carbon nano tubes are isolated from hydrocarbon wax soot and then functionalized by oxidation treatment with an oxidizing agent. The WSNT can contain a pharmaceutical composition for release by a biological degradation agent of the WSNT for example | 2008-09-04 |
20080213368 | Method for Stabilizing Anti-Dementia Drug - The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug. | 2008-09-04 |
20080213369 | SYNTHETIC PLATELETS - A synthetic platelet substitute that interacts with platelets and the (sub)endothelium, comprising: (a) a carrier molecule comprising lipidic particles with a cross-linked surface mesh, the lipidic particles comprising: an inner lipidic particle of pharmaceutically acceptable particle-forming lipids; hydrophilic polymer chains linked to the surface of the lipidic particle, the hydrophilic polymer chains comprising a crosslinkable end group at free ends thereof; and cross-linker groups linking the end groups of the hydrophilic polymer chains to form the cross-linked surface mesh; and (b) at least one receptor molecule attached to the surface of the carrier molecule. The receptor molecule can be a peptide moiety specific for ligands involved in platelet function. | 2008-09-04 |
20080213370 | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof - In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein. | 2008-09-04 |
20080213371 | Rapidly disintegrating solid oral dosage form - Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity. | 2008-09-04 |
20080213372 | Gel and Apparatus for Cleaning and Deodorizing Fluids - A gel for cleaning and deodorizing air includes an organic binder with ultraviolet light permeable polymeric molecules and particles of inorganic semi-conductors. The gel includes acrylic molecules, a polar diluent and an ultraviolet light inert charge including particles of silica, of rutile cristalline form of titanium oxide and/or of clay. | 2008-09-04 |
20080213373 | Particles for Treatment of Pulmonary Infection - Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine. | 2008-09-04 |
20080213374 | NANOPARTICULATE SORAFENIB FORMULATIONS - The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancer, renal cancer, and related diseases. | 2008-09-04 |
20080213375 | Drying of Drug-Containing Particles - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas. | 2008-09-04 |
20080213376 | Medicament that is Intended for Oral Administration, Comprising a Cyclooxygenase-2 Inhibitor, and Preparation Method Thereof - The invention relates to a medicament which is intended for oral administration, which comprises a cyclooxygenase-2 inhibitor and which has improved bioavailability, and to a method of preparing said medicament. The inventive medicament comprises an agglomerate based on inert solid particles based on at least one excipient, said agglomerate comprising a cyclooxygenase-2 inhibitor and at least one hydrophilic polymer. According to the invention, the agglomerate comprises a spray which is applied to the aforementioned particles, consisting of a solution or suspension of micronized grains of the inhibitor in said polymer(s), in order to agglomerate said particles. The inventive method essentially comprises the following steps, namely: (i) the preparation of a sprayable liquid that is based on the micronized grains of said inhibitor in solution or in suspension in at least one hydrophilic polymer; and (ii) the spraying of the liquid onto the solid particles, in order to obtain the agglomerate by means of wet granulation, said agglomerate comprising the grain solution or suspension spray. | 2008-09-04 |
20080213377 | Delivery of Nanoparticles and/or Agents to Cells - The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and/or agents to tissues, cells, and/or subcellular locales. In general, compositions comprise a nanoparticle (e.g. quantum dot, polymeric particle, etc.), at least one modulating entity (such as a targeting moiety, transfection reagent, protective entity, etc.), and at least one agent to be delivered (e.g. therapeutic, prophylactic, and/or diagnostic agent). The present invention provides methods of making and using nanoparticle entities in accordance with the present invention. | 2008-09-04 |
20080213378 | Nanoparticulate statin formulations and novel statin combinations - The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught. | 2008-09-04 |
20080213379 | Tumor environment-induced ligand-expressing nanocarrier system - Drug delivery compositions for specific delivery of a drug to a tumor are described. These compositions include a core for sequestering the drug and a shell to which a ligand is attached for delivery of a drug to target cells. Since normal cells may also be targeted by the ligand, the compositions embed the ligand in the shell until the localized conditions surrounding the tumor cause the ligand to be displayed on the surface of the shell. One composition exhibits shrinkage of the shell at tumor pH, whereas another composition exhibits extension of the ligand at tumor pH. Still another composition causes the ligand to be exhibited at an elevated temperature. | 2008-09-04 |
20080213380 | Process for the Preparation of Encapsulates Through Precipitation - A process for the preparation of encapsulates, employs: a pumpable emulsion having (i) a continuous phase containing a solvent and a matrix-forming solute dissolved in the solvent and (ii) a dispersed phase; an extractant including supercritical, subcritical or liquefied gas; the solvent being substantially more soluble in the extractant than the matrix-forming solute and the process including the successive steps of: a) combining the pumpable emulsion with the extractant under mixing conditions; b) allowing the formation of particulate encapsulates in which the dispersed phase is encased in a solid matrix of the matrix-forming solute; c) collecting the encapsulates and separating them from the extractant. The present processes is particularly suitable for producing particles containing active ingredients that are very sensitive, whose activity is adversely affected by exposure to oxygen, light, moisture, heat and/or friction. | 2008-09-04 |
20080213381 | Oral Drug Delivery System - The present invention provides an oral drug delivery system comprising—
| 2008-09-04 |
20080213382 | THERMOTHERAPY SUSCEPTORS AND METHODS OF USING SAME - Untargeted magnetic nanoparticles exhibiting collective behavior and enhanced heating ability in thermotherapeutic applications are described, as are methods for using such untargeted magnetic nanoparticles. | 2008-09-04 |
20080213383 | FINE PARTICLES OF POORLY WATER-SOLUBLE DRUG HAVING ENTERIC MATERIAL ADSORBED ON PARTICLE SURFACE - The present invention relates to fine particles of a poorly water-soluble drug wherein a predetermined enteric material is adsorbed as the dispersant on the surface of a poorly water-soluble drug, as well as a method for producing the same fine particles. It is possible to efficiently and safely produce in a short amount of time fine particles with which absorption of a poorly water-soluble drug that is poorly absorbed in humans, and the like can be improved, and a pharmaceutical preparation with excellent dispersion stability can be provided, by using the fine particles of the present invention having an improved dissolution profile. | 2008-09-04 |
20080213384 | Ultrasound-Assisted Synthesis of Cyclodextrin-Based Nanosponges - A description is given of substantially spherical nanosponges which can be obtained by crosslinking cyclodextrins and their by-products with organic carbonates as crosslinkers and ultrasounds without a solvent. | 2008-09-04 |
20080213385 | Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin - The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer. | 2008-09-04 |
20080213386 | Nutraceutical for the Prevention and Treatment of Cancers and Diseases Affecting the Liver - A composition comprising vegetable/herbal-based dietary ingredients, or extracts, which contains vitamins and nutrients that provide a novel nontoxic treatment for liver cancers, hepatitis, and liver cirrhosis. The composition can be taken as a daily dietary supplement to enhance normal physiological functions of the body. The said composition, or extracts thereof, are useful and effective in the treatment and prevention of liver and possibly other cancers. The compositions are also useful for administration to patients with pre-existing hepatitis and/or liver cirrhosis. The compositions or extracts thereof may be useful for treating other cancers and other disorders, diseases, or conditions. | 2008-09-04 |
20080213387 | Cytotrophoblast Stem Cell - The invention relates to cytotrophoblast stem cells derived from embryonic stem cells; their differentiation into endovascular cytotrophoblast cells; and uses thereof. | 2008-09-04 |
20080213388 | ECM TO FILL A SPACE CREATED AFTER CANCEROUS TUMOR EXCISION - Methods are described for using exogenous extracellular matrix (ECM) to fill a space created after cancerous tumor excision. The extracellular matrix promotes healing at the tumor excision site. Forms of ECM that can be used include exogenous mammalian ECM in sheets, particulate and emulsion. | 2008-09-04 |
20080213389 | Three-Dimensional Scaffolds for Tissue Engineering Made by Processing Complex Extracts of Natural Extracellular Matrices - Methods of making a biologically active three-dimensional scaffold capable of supporting growth and differentiation of a cell are described. Biologically active three-dimensional scaffold made by the methods of the invention and an engineered tissue made from the scaffolds are described. Fibers of desired porosity can be obtained from non-structural ECM by lyophilization and/or electrospinning which can be useful for numerous tissue engineering applications requiring complex scaffolds, such as wound healing, artificial skin (burns), soft tissue replacement/repair and spinal cord injury. | 2008-09-04 |
20080213390 | Deuterium Depleted Water (Ddw) Using As Adjuvant In Cancer Therapy For Cytostatics Toxicity Reducing - A method is provided for utilizing Deuterium Depleted Water (DDW) as an adjuvant in cancer therapy and for reducing cytostatic toxicity. The method includes administration of DDW having a concentration of about 60 ppm, as a daily diet, to animals. The cancer therapy can include a mono-chemotherapy where a single drug or cytostatic is used or a poly-chemotherapy where more than one drug or cytostatic is used. The drug or cytostatic that are used for chemotherapy can include one or more of Cyclophosphamide, 5-Flourouracil, Farmarubicine and Vinblastine. The method can be used to treat different types of cancer. | 2008-09-04 |
20080213391 | Substance for the Treatment of Infections - The invention relates to the use of dichloric acids and the derivatives thereof for producing medicaments used for disinfecting body cavities. | 2008-09-04 |
20080213392 | Biocidal Ceramic Compositions, Methods and Articles of Manufacture - The present invention provides biocidal ceramic compositions incorporating bioactive ionic species that are chemically bound in a substantially single-phase, crystalline, [NZP]-type structure, methods for producing the crystalline structures, and articles of manufacture incorporating the crystalline structures, and uses of the articles of manufacture. Bioactive ionic species can be, but are not limited to, Ag, Cu, Ni, Zn, Mn, Sn, Co, H, and combinations thereof. | 2008-09-04 |
20080213393 | Colonic purgative composition with soluble binding agent - This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation. | 2008-09-04 |
20080213394 | Polymer-Based Antimicrobial Agents, Methods of Making Said Agents, and Products Incorporating Said Agents - An antimicrobial agent includes a metal ion in a hydrophilic polymer binder or carrier. The metal ion is preferably a silver ion and the hydrophilic polymer preferably comprises a sulfonated polyurethane or sulfonated polystyrene. According to a method of the invention, the antimicrobial agent is dissolved in dimethyl acetamide DMA, applied to paper by spraying, squeegee or the like and dried in an oven to flash off the solvent. The antimicrobial agent can be applied to other products by spraying and/or dipping and then drying to flash off solvent. According to another embodiment of the invention, the antimicrobial agent includes a water soluble polymer, at least one organic acid (e.g., one or more carboxylic acids such as acetic acid, formic acid, citric acid, malefic acid, ascorbic acid, salicyclic acid), and oligodynamic metal ions which react with counter-ions of the polymer such that the metal ions are bound to corresponding counter-ions, and the polymer controls a sustained release of said metal ion. The agent may also include a non-organic acid. (preferably boric acid and/or dictylborate). The water soluble polymer is preferably a sulfonated polymer (e.g., a sulfonated polyurethane, a sulfonated polystyrene, or a mixture thereof). | 2008-09-04 |
20080213395 | Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins - A method for the treatment and/or prophylaxis of disorders of the gastrointestinal system, other disorders selected from post exercise recovery, heat stress, vasovagal states, sleep disorders and fluid loss, and for the maintenance of blood sugar level homeostasis, comprising orally administering to said patient an admixture of vitamins and minerals formulated to have a pH greater than or equal to 5.0 in aqueous solution. | 2008-09-04 |
20080213396 | Copper Lowering Treatment Of Cardiac Disease - The present invention relates generally to the field of prophylaxis and therapy for cardiac fibrosis. In particular, the present invention is related to agents that can bind or complex copper, and to the use of these agents in the prevention and treatment of cardiac damage caused by chemotherapeutic and pharmaceutical agents. | 2008-09-04 |
20080213397 | NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM - The invention provides a nutrient composition for augmenting immune strength or physiological detoxification. The nutrient composition consists of an optimal combination of an effective amount of at least one vitamin antioxidant, at least one mineral antioxidant and a highly saturable amount of at least three high potency antioxidants. The at least one vitamin antioxidant can be vitamin C, bioflavonoid complex, vitamin E, vitamin B6 or beta-carotene and the at least one mineral antioxidant can be zinc or selenium. The at least three high potency antioxidants can be alpha lipoic acid, acetyl L-carnitine, N-acetyl-cysteine, co-enzyme Q10 or glutathione. Also provided is a nutrient composition for augmenting immune strength or physiological detoxification that consists of an optimal combination of an effective amount of at least three vitamin antioxidants, at least two mineral antioxidants and a highly saturable amount of at least three high potency antioxidants. Further provided is a method of stimulating immune system function or a method of augmenting a therapeutic treatment of a disease. The method consists of administering to an individual a nutrient composition of the invention one or more times a day over a period of about 5-7 weeks, the immune system function being stimulated to result in an increase of CD4+ cells of at least about 15% compared to pre-administration levels. A method of stimulating a physiological detoxification function of an individual or a method of augmenting a therapeutic treatment of a disease is also provided. The method consists of administering to an individual a nutrient composition of the invention one or more times a day over a period of about 5-7 weeks, the physiological detoxification function being stimulated to result in a decrease of one or more free radical markers by about 20% compared to pre-administration levels. | 2008-09-04 |
20080213398 | Modified Azole Compounds as Antifungal and Antibacterial Agents - The present invention relates to the compounds of formula (I), their preparation and use as antifungal and/or antibacterial agents. | 2008-09-04 |
20080213399 | Combination Therapies Using Hdac Inhibitors - The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount. | 2008-09-04 |
20080213400 | Combinations of Chromium with Antidiabetics for Glucose Metabolism Disorders - Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium. | 2008-09-04 |
20080213401 | NUTRITIONAL SUPPLEMENTS FOR HEALTHY MEMORY AND MENTAL FUNCTION - The invention relates to compositions for supporting healthy memory and optimizing mental energy and methods for improving, preventing, and treating mental disorders or deterioration. The compositions of the invention can be formulated as nutritional or dietary supplements. | 2008-09-04 |
20080213402 | Composition For Preparing Carbon Dioxide External Preparation - The invention is directed to a composition for preparing a carbon dioxide external preparation characterized by comprising a substance generating an acid after being hydrolyzed, a carbonate, a thickener and water as essential components, and a composition for preparing a carbon dioxide external preparation characterized by comprising the essential components above, a gelating agent being gelated by a calcium ion and a water-insoluble or poorly soluble calcium salt. According to the invention, the carbon dioxide external preparation, which contains sufficient amount of carbon dioxide, from which the carbon dioxide is absorbed transdermally or transmucosally in a sustained manner, and which has a more potent cosmetic or medical effect, can be easily prepared. In addition, the composition for preparing a carbon dioxide external preparation with a low cost can be provided. | 2008-09-04 |
20080213403 | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide - The present invention provides a method for treating a pulmonary disease state in mammals by protecting indigenous in vivo levels of nitric oxide in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of a nitric oxide mediator, wherein the nitric oxide mediator is selected from the group consisting of α-keto acids having four or more carbon atoms, precursors of α-keto acids having four or more carbon atoms, and the salts thereof. | 2008-09-04 |
20080213404 | Hif Modulating Compounds and Methods of Use Thereof - A method is provided for treating subjects, including humans, with infection or virulence by pathogens. The method involves administering an agent in amounts effective to eradicate or reduce infections and/or an inflammatory response caused by pathogens. Methods for identifying compounds useful as anti-infectives that decrease the immune resistance, virulence, or growth of microbes are also provided. More particularly, there are provided methods for identifying compounds which increase accumulation or stability or activity, or alternatively decrease the degradation of HIF-1a protein. | 2008-09-04 |
20080213405 | Pharmaceutical compositions containing bulbophyllum and their use for treating illnesses - Described are pharmaceutical compositions containing | 2008-09-04 |
20080213406 | Compositions and methods for enhancing cognitive function - Disclosed are compositions for promoting general health and well-being, comprising an extract of a botanical raw material, wherein said extract inhibits the carboxyl demethylating activity of a protein phosphatase, and methods of making and using same. | 2008-09-04 |
20080213408 | Insect Repellent - The invention provides compositions and methods useful in repelling target pests, such as insects from target areas. The compositions comprise mixtures or solutions of at least one repellent composition. The compositions of the invention preferably include an effective amount of evening primrose oil (“EPO”) to repel a target pest from a target area, such as animals, humans, plants or building structures, along with a carrier. The repellent composition may include a combination of EPO with another plant extract oil and a combination of EPO with catnip oil, optionally combined with another plant extract oil. The method for repelling target pests from animals comprises contacting a target area with the repellent composition to repel the target pest from the target area. The method also reduces transmission of infectious diseases transmitted by target pests by reducing contact of the pest with target areas. | 2008-09-04 |
20080213409 | Triple anti-irritant composition - The present invention relates to a composition comprising two or more anti-irritants, each having at least about 7.2% oxygen content. In a separate embodiment, the composition may be defined to include a skin conditioning agent, a skin protectant agent, and an anti-irritant agent, each having an oxygen content of at least about 7.2%. The invention further comprises methods of treating and preventing skin conditions by applying the composition to the skin, and then optionally washing the skin. | 2008-09-04 |
20080213410 | ANTI-HUMAN PAPILLOMAS VIRUS TOPICAL COMPOSITION - The present invention relates to a topical composition for reducing lesion and inflammation of human papillomavirus (HPV) on the skin and mucous membranes comprising an effective amount of at least one component from one of ground garlic, garlic powder, garlic oil, minced garlic, and greater celandine, a terpene-, phenol- or polyphenol-containing agent, and a sulfurated compound in association with a pharmaceutically acceptable carrier to form a homogenous topical composition, and method of treatment thereof. | 2008-09-04 |
20080213411 | Cancer metastasis inhibitory composition - It is intended to provide a cancer metastasis inhibitor which shows a potent effect of inhibiting cancer metastasis comparable to bikunin, has no side effect and can be obtained in a large amount at a low cost. As the results of studies on the cancer metastasis inhibitory effect by administration of soybean Kunitz trypsin inhibitor (KTI), a potent activity of inhibiting cancer metastasis was found out. Since KTI is contained in soybean whey, which is yielded in a large amount in preparing isolated soybean protein and the like from soybeans, and soybean whey can be obtained at a low cost, KTI extracted and purified in a large amount from soybean whey is clinically applicable. | 2008-09-04 |
20080213412 | SAFE AND STABLE EDIBLE MATERIAL HAVING REINFORCED CONCRETE-LIKE STRUCTURE - It is intended to provide a stable and safe edible material. By mixing a dehydrated edible fiber mass and an edible non-fiber material, an edible material, which is superior in shape retention properties to the dehydrated edible fiber mass and the edible non-fiber material, can be obtained. This edible material has a high stability and a high safety because of having a reinforced concrete-like structure wherein the edible fiber serves as the reinforcing steel while the edible non-fiber material serves as the concrete. A liquid oil such as EV olive oil, rapeseed oil, sesame oil or soybean oil can be easily and safely converted into a solid fat merely by adding from 2 to 3% of a popular food material that has been naturally and safely taken since early times. In producing the above edible material, no trans processing that has been warned as the dangerousness thereof by the governments and public corporations in Europe, USA and Canada is needed. Moreover, this edible material sustains a favorable hardness within a temperature range of from −20° C. to 200° C. without becoming too hard at low temperatures as margarine or melting at high temperatures. When put into the mouth, however, it quickly liquefies and tastes wonderful. Water may be added thereto, though it is not always necessary. It prevents butter or chocolate from melting even at +200° C. Furthermore, a convenient and tough edible plastic material can be obtained therefrom without needing water. | 2008-09-04 |
20080213413 | COMPOSITIONS CONTAINING CAPSINOIDS - Problem to be Solved | 2008-09-04 |
20080213414 | Compositions containing phaseolus vulgaris extract and alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes - A process for treating an individual suffering from obesity and type II diabetes in which said individual is caused to ingest a composition comprising (1) a kidney bean extract with a standarized phaseolamine content and (2) | 2008-09-04 |
20080213415 | Treatment of Glaucoma and Diabetic Retinopathy with Morinda Citrifolia Enhanced Formulations - The present invention relates to methods and formulations directed inhibiting carbonic anhydrase, fatty acid amide hydrolase and endothelin-converting enzymes comprising the administration of processed | 2008-09-04 |
20080213416 | Composition Containing an Extract of Rubi Fructus for Preventing and Treating Anxiety, Depression and Dementia, and Improving Memory - Disclosed is a composition containing an extract of Rubi Fructus for preventing and treating anxiety, depression and dementia and improving memory. The composition can be used as drugs and dietary supplements which induce prophylactic and therapeutic effects on anxiety, depression and dementia as well as memory-improving effect in the moderns afflicted with the modification of neurotransmitter releases and brain damage caused by external environmental factors including various kinds of stresses, menopause, drinking alcohols, smoking cigarettes and others. | 2008-09-04 |